0001209191-23-054169.txt : 20231102
0001209191-23-054169.hdr.sgml : 20231102
20231102165248
ACCESSION NUMBER: 0001209191-23-054169
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231031
FILED AS OF DATE: 20231102
DATE AS OF CHANGE: 20231102
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Roth David
CENTRAL INDEX KEY: 0001599014
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37813
FILM NUMBER: 231373307
MAIL ADDRESS:
STREET 1: C/O SYROS PHARMACEUTICALS, INC.
STREET 2: 620 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Syros Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001556263
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 453772460
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 35 CAMBRIDGE PARK DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
BUSINESS PHONE: 617-744-1340
MAIL ADDRESS:
STREET 1: 35 CAMBRIDGE PARK DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
FORMER COMPANY:
FORMER CONFORMED NAME: LS22, Inc.
DATE OF NAME CHANGE: 20120815
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-10-31
0
0001556263
Syros Pharmaceuticals, Inc.
SYRS
0001599014
Roth David
C/O SYROS PHARMACEUTICALS, INC.
35 CAMBRIDGEPARK DRIVE
CAMBRIDGE
MA
02140
0
1
0
0
Chief Medical Officer
0
Common Stock
2023-10-31
4
M
0
18875
A
18875
D
Common Stock
2023-11-01
4
F
0
6301
2.22
D
12574
D
Restricted Stock Units
2023-10-31
4
M
0
18875
0.00
D
Common Stock
18875
18875
D
Represents shares of common stock received upon vesting of a restricted stock unit award.
Represents shares used to cover tax withholding on a restricted stock unit release.
Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on October 31, 2023, and are scheduled to vest as to one half (50%) of the shares on October 31, 2024.
/s/ Todd Rosenthal, as attorney-in-fact
2023-11-02